NASDAQ:OREX - Orexigen Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.22 0.00 (0.00 %) (As of 05/22/2019 03:19 PM ET)Previous Close$0.2229Today's Range$0.2229 - $0.222952-Week Range$0.17 - $3.81VolumeN/AAverage Volume1.16 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products primarily in the United States, Europe, and South Korea. It offers Contrave for the treatment of obesity. The company also offers Contrave under the Mysimba brand name. Orexigen Therapeutics, Inc. was founded in 2002 and is headquartered in La Jolla, California. On March 12, 2018, Orexigen Therapeutics, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. Receive OREX News and Ratings via Email Sign-up to receive the latest news and ratings for OREX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:OREX Previous Symbol CUSIP68616410 CIK1382911 Webhttp://www.orexigen.com/ Phone858-875-8600Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding SharesN/AMarket CapN/A Next Earnings DateN/A OptionableNot Optionable Orexigen Therapeutics (NASDAQ:OREX) Frequently Asked Questions What is Orexigen Therapeutics' stock symbol? Orexigen Therapeutics trades on the NASDAQ under the ticker symbol "OREX." How were Orexigen Therapeutics' earnings last quarter? Orexigen Therapeutics, Inc. (NASDAQ:OREX) released its quarterly earnings results on Monday, November, 13th. The biopharmaceutical company reported ($1.35) earnings per share for the quarter, beating the consensus estimate of ($2.13) by $0.78. The biopharmaceutical company had revenue of $18.90 million for the quarter, compared to analysts' expectations of $24.20 million. The business's quarterly revenue was up 170.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.12 EPS. View Orexigen Therapeutics' Earnings History. Has Orexigen Therapeutics been receiving favorable news coverage? Media coverage about OREX stock has been trending somewhat negative recently, InfoTrie Sentiment reports. The research firm identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Orexigen Therapeutics earned a coverage optimism score of -1.1 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the near term. Who are some of Orexigen Therapeutics' key competitors? Some companies that are related to Orexigen Therapeutics include Advanced Accelerator Application (AAAP), American Oriental Bioengineering (AOBI), Aralez Pharmaceuticals (ARLZ), ARMO Biosciences (ARMO), Bohai Pharmaceuticals Group (BOPH), Cardiome Pharma (CRME), Concordia International (CXRXD), Concordia International (CXRX), Depomed (DEPO), Egalet (EGLT), Eleven Biotherapeutics (EBIO), Epirus Biopharmaceuticals (EPRSQ), ERBA Diagnostics (ERBA), FutureWorld (FWDG) and GlobeImmune (GBIM). What other stocks do shareholders of Orexigen Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Orexigen Therapeutics investors own include Lexicon Pharmaceuticals (LXRX), Arena Pharmaceuticals (ARNA), ImmunoGen (IMGN), MannKind (MNKD), Novavax (NVAX), Opko Health (OPK), Synergy Pharmaceuticals (SGYP), Biogen (BIIB), Inovio Pharmaceuticals (INO) and Twitter (TWTR). Who are Orexigen Therapeutics' key executives? Orexigen Therapeutics' management team includes the folowing people: Mr. Michael A. Narachi, Pres, Chief Exec. Officer & Director (Age 59)Dr. Thomas R. Cannell D.V.M., Exec. VP, COO & Pres of Global Commercial Products (Age 56)Mr. Thomas P. Lynch, Exec. VP, Gen. Counsel, Chief Admin. Officer & Sec. (Age 51)Ms. Monica Forbes, VP & Acting CFO (Age 42)Mr. Stephen A. Moglia, Chief Accounting Officer, VP and Controller (Age 53) How do I buy shares of Orexigen Therapeutics? Shares of OREX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Orexigen Therapeutics' stock price today? One share of OREX stock can currently be purchased for approximately $0.2229. What is Orexigen Therapeutics' official website? The official website for Orexigen Therapeutics is http://www.orexigen.com/. How can I contact Orexigen Therapeutics? Orexigen Therapeutics' mailing address is 3344 N. TORREY PINES CT. SUITE 200, LA JOLLA CA, 92037. The biopharmaceutical company can be reached via phone at 858-875-8600 or via email at [email protected] MarketBeat Community Rating for Orexigen Therapeutics (NASDAQ OREX)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 233 (Vote Outperform)Underperform Votes: 266 (Vote Underperform)Total Votes: 499MarketBeat's community ratings are surveys of what our community members think about Orexigen Therapeutics and other stocks. Vote "Outperform" if you believe OREX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OREX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/22/2019 by MarketBeat.com StaffFeatured Article: Economic Reports Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.